Evidence map›Paper›PMID 39316609›Full record

ArticlePLoS pathogens2024

Changes in cerebrospinal fluid proteins across the spectrum of untreated and treated chronic HIV-1 infection.

Zicheng Hu, Paola Cinque, Ameet Dravid, Lars Hagberg, Aylin Yilmaz, Henrik Zetterberg, Dietmar Fuchs, Johanna Gostner, Kaj Blennow, Serena S Spudich and 6 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Zicheng HuBakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, United States of America.
Paola CinqueUnit of Neurovirology, San Raffaele Hospital, Milan, Italy.
Ameet DravidHIV Medicine and Infectious Diseases, Poona Hospital and Research Centre, Pune, India.
Lars HagbergDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Aylin YilmazDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Henrik ZetterbergInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Dietmar FuchsInstitute of Medical Biological Chemistry, Innsbruck Medical University, Innsbruck, Austria.
Johanna GostnerInstitute of Medical Biological Chemistry, Innsbruck Medical University, Innsbruck, Austria.
Kaj BlennowInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Serena S SpudichDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Laura KincerDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Shuntai ZhouDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Sarah Beth JosephDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Ronald SwanstromLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Richard W PriceDepartment of Neurology, University of California San Francisco, San Francisco, California, United States of America.ORCID 0000-0001-5429-6044
Magnus GisslénDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Persistent CSF HIV despite successful cART: Viral Tropism, Drug Penetration andP01MH094177 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SWANSTROM, RONALD I · 2011 to 2015
$4.5M
Compartmentalized CSF viral escape and the CNS HIV reservoirR01NS094067 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRICE, RICHARD W. · 2015 to 2020
$3.9M
CSF & Lymphocyte Dynamics in HIV InfectionR01MH062701 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRICE, RICHARD W. · 2000 to 2010
$3.5M
The Cerebrospinal Fluid Proteome in HIV-1 Infection and Opiate AddictionP01DA026134 · NIDA · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI SMITH, RICHARD D · 2008 to 2010
$3.0M
The Neuropathobiology of Primary HIV-1 InfectionR01MH081772 · NIMH · YALE UNIVERSITY · PI SPUDICH, SERENA S · 2008 to 2013
$2.7M
Treatment&Pathogenesis of Cerebrospinal Fluid HIV InfectR01NS037660 · NINDS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI PRICE, RICHARD W · 1998 to 2004
$1.7M
CSF Molecular Marker Study ConsortiumR01NS043103 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRICE, RICHARD W · 2002 to 2006
$1.4M
Defining CNS HIV Infection in Treated Patients: Foundation for EradicationR21MH096619 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRICE, RICHARD W. · 2012 to 2013
$390k
Pilot Study of Treatment Augmentation on CNS Immunoactivation in Treated HIV-1 InR21MH083520 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRICE, RICHARD W. · 2008 to 2009
$386k
NCATS NIH HHS UL1 TR001863NIDA NIH HHS P01 DA026134NIMH NIH HHS P01 MH094177NIMH NIH HHS R01 MH062701NIMH NIH HHS R01 MH081772NIMH NIH HHS R21 MH083520NIMH NIH HHS R21 MH096619NINDS NIH HHS R01 NS037660NINDS NIH HHS R01 NS043103NINDS NIH HHS R01 NS094067
6 · The paper itself

Abstract

Using the Olink Explore 1536 platform, we measured 1,463 unique proteins in 303 cerebrospinal fluid (CSF) specimens from four clinical centers contributed by uninfected controls and 12 groups of people living with HIV-1 infection representing the spectrum of progressive untreated and treated chronic infection. We present three initial analyses of these measurements: an overview of the CSF protein features of the sample; correlations of the CSF proteins with CSF HIV-1 RNA and neurofilament light chain protein (NfL) concentrations; and comparison of CSF proteins in HIV-associated dementia (HAD) and neurosymptomatic CSF escape (NSE). These reveal a complex but coherent picture of CSF protein changes with highest concentrations of many proteins during CNS injury in the HAD and NSE groups and variable protein changes across the course of systemic HIV-1 progression that included two common patterns, designated as lymphoid and myeloid patterns, related to principal involvement of their underlying inflammatory cell lineages. Antiretroviral therapy reduced CSF protein perturbations, though not always to control levels. The dataset of these CSF protein measurements, along with background clinical information, is posted online. Extended studies of this unique dataset will supplement this report to provide more detailed characterization of the dynamic impact of HIV-1 infection on the CSF proteome across the spectrum of HIV-1 infection, advancing the mechanistic understanding of HIV-1-related CNS pathobiology.

Indexed as

Cerebrospinal Fluid ProteinsHIV-1HIV InfectionsAdultAIDS Dementia ComplexBiomarkersChronic DiseaseFemaleHumansMaleMiddle AgedBiomarkersCerebrospinal Fluid Proteins

Identifiers

PMID39316609
PMCPMC11469498

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.